Refraction following PRK stable over eight years

Article

Postoperative refraction following photorefractive keratectomy (PRK) remains stable from the second year postoperatively through to eight years.

Postoperative refraction following photorefractive keratectomy (PRK) remains stable from the second year postoperatively through to eight years, according to Hossein Mohammad Rabei and colleagues from the Basir Eye Center, Tehran, Iran.

The researchers obtained data from 2,141 myopic patients who underwent PRK with single-step method using a NIDEK EC-5000 excimer laser with 5-6 mm ablation zones in Basir Eye Center, Tehran during 1994-1996.

A total of 179 myopic eyes of 98 patients who had undergone PRK and completed eight years follow-up were included in the study. Follow-up examinations were performed one, three, six and 12 months and two and eight years after surgery. The treated eyes were divided into three groups according to preoperative refraction: low myopes, medium myopes and high myopes.

After eight years follow-up, the percentage of eyes within ±1 D of emmetropia was 69.1%, 30% and 46.2% in the low, medium and high groups, respectively. Changes in myopic regression stabilized in all myopic groups within two years and was significantly correlated to preoperative spherical equivalent refraction. Corneal haze was recorded in 5% but cleared within two years in 89% of cases.

The results of this long-term study demonstrate that refraction following PRK does remain stable for up to eight years following surgery.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.